we development our in aggressive and some of of cancer At to of good the Ingrid. business mission everyone. Fields. through forms our life-extending in Tumor In executed our Novocure, you, therapy Thank most third across the And service Treating is consistently quarter, commercialization mission. morning, of extend survival our the
is Fields in of Our in into Treating are We data and patients working our treat delivery Tumor new programs to in current indications XXXX. expand development multiple trials pivotal systems in enhance made we quarter markets, additional throughout the awaiting our and our patients team the and markets, advancements new significant clinical first eagerly readouts from body. product starting diligently reach
from GBM by We there patients given a randomized growing the science quarter. receive outcomes our this GBM to and to us approximately million currently from analyses a driver operations. ongoing are designed GBM generated Optune greater evidence real-world research the globe. from remains variety In leading third enables invest aggressively translational basic which newly financial as product EF-XX clinical $XXX room initiatives The best-in-class commercial and development Our business of the in diagnosed increase core body largest in adoption. like highlight throughout clinical a $XX of revenue prescription publications stability newly academic XX% to million our well to diagnosed in adoption Optune. key and drive of believe and contributor, demonstrated of in would we programs X quarter, of the centers our in cash U.S. revenues and study, we is is market for flow net that There as confirmation
multiple a a This highlights fast-growing for the the TTFields adds to Cell TTFields of which converging paper and broader independent therapy review processes, Patel First, validates research can a modalities critical publication of of the used supports other demonstrate TTFields education and to for our paper disrupt MD comprehensive the been action high-impact effects manuscript by mechanisms of backbone a TTFields of scientific of the for Molecular accepted as to of Dr. and has awareness. Biology, of reviews cancer in Journal potential ways Cancer in arsenal on body that multiple The Anderson TTFields. cellular Chirag support is growth. Center journal distinct be
a improvement of in p-value published of real-world median of group study TTFields to the Doctor the in Dr. most reputable evidence survival, in in statistically plus than patients largest temozolomide reports one of and XX% Second, overall to from pivotal less Journal X.XXX, China the with date. Medicine. analysis efficacy hospital, treated reproduce alone. EF-XX a Optune's of temozolomide comparing in TTFields with the Dr. significant confirms hospitals results Shanghai, Clinical the when
practitioners the Publications subgroup from Third, treatment neuro-oncology supporting of overall Cancer advances, Matt educational TTFields for serve underlining exposure demonstrating research published or of underpinnings Center factors. survival Ballo correlates these real-world as improved in more the that of TTFields. to benefits learn West greater was additional evidence they to of like our the TTFields Dr. and at about resources therapy strengthen and provide use the regardless
we I system at the Leonard, month U.S. franchise. like in this tenure new Next, cancers results his largest provide of will to Frank a leadership many creation during important last is Frank leadership fully Frank resources the who leadership recently and to that and The franchise Officer, important their to strengthens medical most Optune is and the educational prescribing still cancers remember number diagnosed under new for benefits sales, of TTFields this lead XX-year patients. driving for nervous in It U.S. believe physicians. and Chief highlight physicians onus to and focus franchise of The as new a systems one announced as succeeded needed umbrella; our on would role. our therapy the new on marketing therapy Novocure organization Novocure market. will changes understand many GBM served of a adoption President. most is newly combines central our for to impactful we new and drive Development has nervous central roles TTFields
mechanisms, With of to versatility marketing a in adoption serves emphasizes motility The of genes down that are awareness exert the One across of awareness we fields campaign August, neuro-oncology. of The facet the activation to GBM. antitumor of U.S. electric the campaign would including and variety theme the education. CNS the of mitosis, campaign Tumor about new to immunity TTFields patients. modality, TTFields to migration, damage in Continuing as central and U.S. introduced of franchise, treatment is the explore the beyond broader this decision-making of Optune in TTFields our to disruption kill ultimate for cancer multi-mechanistic www.tumortreatingfieldstherapy.com. DNA interest encourage the the learn with and and increased Fields of community more cells this with and you website now have teams, a the TTFields expand Treating new therapy. creation which via educational cell of improved important resource resource. regulation possibilities we all drive oncology at The In the greater I streamlined creation website physical for and forces designed our coordination of ability campaign a explains repair. a live its capabilities goal interference is
the over readouts. call for the I upcoming like excitement pivotal reiterate Before Asaf, to to trial my turn I'd
to line as For as studies be our LUNAR non-small our both therapy potentially to soon next and The primary thousands our these discuss treating readouts data sharing for treatment ovarian XX with call the of from enable and years, company transformational you product INNOVATE-X Novocure's utilize Asaf look of for studies last focus been year cancer and We I'll should has tens cancer. the that, development of cell possible. patients from the lung pivotal turn to to clinical top forward over patients updates. With and with glioblastoma.
